bplist00—_WebMainResource’	
^WebResourceURL_WebResourceFrameName_WebResourceData_WebResourceMIMEType_WebResourceTextEncodingName_Thttps://www.sec.gov/Archives/edgar/data/1668243/000119312519253710/d778092dex993.htmPOjﬂ<html><head></head><body bgcolor="WHITE"><document>
<type>EX-99.3
<sequence>4
<filename>d778092dex993.htm
<description>EX-99.3
<text>

<title>EX-99.3</title>

 


<center><div style="width:8.5in" align="left">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="right"><b>Exhibit 99.3 </b></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="center"><b>UroGen Investor Day Details Positive Clinical Updates, <font style="white-space:nowrap">UGN-101</font> Launch Preparedness, and Pipeline Advances
</b></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="center"><i><font style="white-space:nowrap">UGN-101</font> and <font style="white-space:nowrap">UGN-102</font> Demonstrate Positive Clinical Data in <font style="white-space:nowrap">Low-Grade</font> Upper Tract Urothelial Cancer (LG UTUC) and <font style="white-space:nowrap">Low-Grade</font> <font style="white-space:nowrap">Non-Muscle</font> Invasive Bladder Cancer (LG NMIBC) </i></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="center"><i><font style="white-space:nowrap">UGN-101</font> Final Data Modules for NDA Submission <font style="white-space:nowrap">On-Track</font> for Q4 2019
</i></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="center"><i><font style="white-space:nowrap">UGN-101</font> Plans for Launch Readiness by January 2020 </i></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" align="center"><i><font style="white-space:nowrap">UGN-201</font> Plans for Advancement into Phase 1 for High-Grade NMIBC in 2020 </i></p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">NEW YORK,&nbsp;September 24, 2019&nbsp;‚Äî&nbsp;UroGen Pharma Ltd.&nbsp;(Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address
unmet needs in the field of urology, today presented updates on its advancing pipeline for urologic cancers and <font style="white-space:nowrap">UGN-101</font> launch readiness at its Investor Day in New York on September&nbsp;24, 2019. </p>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">‚ÄúAt UroGen, we are 100&nbsp;percent committed to overcoming obstacles that have stunted much needed innovation in
<font style="white-space:nowrap">uro-oncology,‚Äù</font> said Liz Barrett, President and Chief Executive Officer of UroGen. ‚ÄúWhile we prepare for a potential launch of <font style="white-space:nowrap">UGN-101,</font> we believe this is just
the beginning of what is possible with our pipeline. The data from an interim analysis for <font style="white-space:nowrap">UGN-102</font> unveiled at our Investor Day further highlight the potential of our RTGel<sup style="font-size:85%; vertical-align:top">‚Ñ¢</sup> platform to transform treatments in this space for an even larger patient population with bladder cancer. We look forward to pushing innovation beyond our foundational platform and moving <font style="white-space:nowrap">UGN-201,</font> our TLR 7/8 agonist for high-grade bladder cancer, into clinical studies in 2020.‚Äù </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">UroGen detailed data updates for
its lead investigational product candidates <font style="white-space:nowrap">UGN-101</font> and <font style="white-space:nowrap">UGN-102:</font> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><b><font style="white-space:nowrap">UGN-101</font></b> (mitomycin gel) for instillation for patients with <font style="white-space:nowrap">low-grade</font> upper tract urothelial cancer (LG UTUC): </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Complete response (CR) rate of 59&nbsp;percent observed in 71 patients with LG UTUC from Phase 3 OLYMPUS trial. Data remain
consistent with previously presented data. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Durability of response determined to be 89&nbsp;percent at six months and 84&nbsp;percent at twelve months.
</p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In the OLYMPUS trial, the most common treatment emergent adverse events (TEAE) included ureteral stenosis, urinary tract
infection, hematuria, flank pain, dysuria, renal impairment, hydronephrosis and frequency. Most TEAEs were characterized as mild to moderate and transient. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">At the time of database lock, the most common Grade 3 TEAE‚Äôs included ureteral stenosis (8.5%), hematuria, flank pain,
and urinary tract infection (3% each). There was one Grade 4 TEAE of subdural hematoma (1.4%). </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Rolling NDA submission is on track for Q4 2019 with potential approval and launch in 1H 2020. </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">If approved, <font style="white-space:nowrap">UGN-101</font> will be the first drug for the primary chemoablative treatment
of LG UTUC. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><b><font style="white-space:nowrap">UGN-102</font></b> (mitomycin gel) for intravesical instillation for patients with
intermediate risk <font style="white-space:nowrap">low-grade</font> <font style="white-space:nowrap">non-muscle</font> invasive bladder cancer (LG NMIBC): </p></td></tr></tbody></table>
</div></center>


<p style="page-break-before:always">
</p><hr size="3" style="COLOR:#999999" width="100%" align="CENTER">


<center><div style="width:8.5in" align="left">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In an interim analysis, 63% (20/32) of patients from the Phase 2b OPTIMA II trial achieved a CR. </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">In an interim analysis, the most common treatment emergent adverse events (TEAEs) observed were dysuria, pollakiuria,
fatigue, hematuria and urinary tract infection. The majority were characterized as mild or moderate and transient. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Patients will continue to be followed with <font style="white-space:nowrap">12-month</font> durability to be reported at a
later date. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Trial enrolled patients with intermediate risk LG NMIBC, defined as those with one or two of the following criteria:
multifocal disease, large tumors and rapid rates of recurrence. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Trial completed enrollment of 62 patients ahead of schedule. </p></td></tr></tbody></table>
<p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="10%">&nbsp;</td>
<td width="2%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Company intends to initiate a pivotal Phase 3 trial in 2020 following discussion with the FDA. </p></td></tr></tbody></table>
<p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">UroGen discussed its ongoing activities to build awareness of unmet needs in UTUC, educate the market and commercialize <font style="white-space:nowrap">UGN-101</font>
following anticipated regulatory approval: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Increased scientific awareness of <font style="white-space:nowrap">UGN-101</font> clinical data developments in urologic
community. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Engagement with payers and proactive market access strategy to ensure patient access and reimbursement.
</p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><font style="white-space:nowrap">UGN-101</font> treatment expected to fit well into existing physician reimbursement
models. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Planned convenience kit for <font style="white-space:nowrap">UGN-101</font> will facilitate preparation and administration
for practitioners. </p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Experienced commercial team with track record of success in <font style="white-space:nowrap">uro-oncology.</font>
</p></td></tr></tbody></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
<tbody><tr style="page-break-inside:avoid">
<td width="5%">&nbsp;</td>
<td width="3%" valign="top" align="left">‚Ä¢</td>
<td width="1%" valign="top">&nbsp;</td>
<td align="left" valign="top"> <p align="left" style=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Nimble salesforce with seven Regional Business Managers (RBMs) hired, and 50 sales reps to be hired by end of 2019.
</p></td></tr></tbody></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Company also provided an update on <b><font style="white-space:nowrap">UGN-201</font></b>, it‚Äôs investigational TLR 7/8 agonist for the
treatment of high-grade NMIBC. <font style="white-space:nowrap">UGN-201</font> is believed to stimulate innate and adaptive antitumor immunity. It likely works in conjunction with other potent immunoregulatory molecules. Nonclinical data shows an
efficacy signal when <font style="white-space:nowrap">UGN-201</font> is administered locally with anti-CTLA4 antibody in a murine model of high-grade bladder cancer. The Company plans to optimize combinations and advance into human studies. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><b>About <font style="white-space:nowrap">UGN-101</font> </b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><font style="white-space:nowrap">UGN-101</font> (mitomycin gel) for instillation is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of <font style="white-space:nowrap">low-grade</font> upper tract urothelial
cancer (LG UTUC). Utilizing the RTGel<sup style="font-size:85%; vertical-align:top">‚Ñ¢</sup> technology platform, UroGen‚Äôs proprietary sustained release, hydrogel-based formulation, <font style="white-space:nowrap">UGN-101</font> is
designed to enable longer exposure of urinary tract tissue to mitomycin, thereby enabling the treatment of tumors by <font style="white-space:nowrap">non-surgical</font> means. <font style="white-space:nowrap">UGN-101</font> is delivered to patients
using standard ureteral catheters. The Company initiated its rolling submission of the <font style="white-space:nowrap">UGN-101</font> New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in December 2018. The FDA previously
granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to <font style="white-space:nowrap">UGN-101</font> for the treatment of UTUC. If approved, <font style="white-space:nowrap">UGN-101</font> would be the first drug approved for
the <font style="white-space:nowrap">non-surgical</font> treatment of LG UTUC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><b>About <font style="white-space:nowrap">UGN-102</font> </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><font style="white-space:nowrap">UGN-102</font> (mitomycin gel) for instillation is an investigational drug formulation of mitomycin in Phase 2b development for the
treatment of <font style="white-space:nowrap">low-grade</font> <font style="white-space:nowrap">non-muscle</font> invasive bladder cancer (LG NMIBC). Utilizing the RTGel<sup style="font-size:85%; vertical-align:top">‚Ñ¢</sup> Technology Platform,
UroGen‚Äôs proprietary sustained release, hydrogel-based formulation, <font style="white-space:nowrap">UGN-102</font> is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by <font style="white-space:nowrap">non-surgical</font> means. <font style="white-space:nowrap">UGN-102</font> is delivered to patients using standard intravesical catheters. The Company completed enrollment in the Phase 2b OPTIMA II trial of <font style="white-space:nowrap">UGN-102</font> for the </p>
</div></center>


<p style="page-break-before:always">
</p><hr size="3" style="COLOR:#999999" width="100%" align="CENTER">


<center><div style="width:8.5in" align="left">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
treatment of LG NMIBC in September 2019 and intends to advance the program to a pivotal study to further investigate <font style="white-space:nowrap">UGN-102</font> in the treatment of this
condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><b>About UroGen Pharma Ltd. </b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">UroGen Pharma Ltd. (Nasdaq:URGN) is
a clinical-stage biopharmaceutical company developing advanced <font style="white-space:nowrap">non-surgical</font> treatments to address unmet needs in the field of urology, with a focus on <font style="white-space:nowrap">uro-oncology.</font>
UroGen has developed RTGel<sup style="font-size:85%; vertical-align:top">‚Ñ¢</sup> reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing
drugs. UroGen‚Äôs sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen‚Äôs lead investigational candidates, <font style="white-space:nowrap">UGN-101</font> (mitomycin gel) for instillation, and <font style="white-space:nowrap">UGN-102</font> (mitomycin gel) for intravesical instillation, are designed to potentially ablate tumors by <font style="white-space:nowrap">non-surgical</font> means and to treat several forms of <font style="white-space:nowrap">non-muscle</font> invasive urothelial cancer, including <font style="white-space:nowrap">low-grade</font> upper tract urothelial
cancer and <font style="white-space:nowrap">low-grade</font> <font style="white-space:nowrap">non-muscle</font> invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel. </p>
<p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><b>Forward-Looking Statements </b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This press release contains forward-looking
statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of <font style="white-space:nowrap">UGN-101</font> for LG UTUC; the timing for completion of the rolling NDA for
<font style="white-space:nowrap">UGN-101;</font> the potential approval of <font style="white-space:nowrap">UGN-101</font> and the timing thereof; the expectation that <font style="white-space:nowrap">UGN-101,</font> if approved, will be the first
drug approved for the <font style="white-space:nowrap">non-surgical</font> treatment of LG UTUC; the timing for completion of <font style="white-space:nowrap">pre-commercial</font> activities and infrastructure
<font style="white-space:nowrap">build-out</font> in anticipation of a potential commercial launch of <font style="white-space:nowrap">UGN-101;</font> the expected readiness of UroGen for a potential commercial launch of <font style="white-space:nowrap">UGN-101</font> in 1H 2020 and the strength and timing of the potential commercial launch of <font style="white-space:nowrap">UGN-101;</font> plans for the retention of field-based personnel in support of the launch of <font style="white-space:nowrap">UGN-101;</font> the potential of UroGen‚Äôs proprietary RTGel<sup style="font-size:85%; vertical-align:top">‚Ñ¢</sup> technology platform to improve therapeutic profiles of existing drugs; the opportunity and
potential of <font style="white-space:nowrap">UGN-102</font> for LG NMIBC; plans to commence a pivotal trial for <font style="white-space:nowrap">UGN-102</font> in LG NMIBC in 2020; <font style="white-space:nowrap">UGN-102‚Äôs</font> potential to
replace current standard of care in LG NMIBC; and plans to initiate a Phase 1 study with <font style="white-space:nowrap">UGN-201.</font> These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited
to: the timing and success of clinical trials, including the OLYMPUS Phase 3 trial and the OPTIMA II Phase 2b trial and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at
all; the ability to maintain regulatory approval; complications associated with achieving commercial readiness for the launch of a new product; the labeling and packaging for any approved product; the scope, progress and expansion of developing and
commercializing UroGen‚Äôs product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof <font style="white-space:nowrap"><font style="white-space:nowrap">vis-√†-vis</font></font>
alternative therapies; and UroGen‚Äôs ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk
Factors section of UroGen‚Äôs Form <font style="white-space:nowrap">10-Q</font> filed with the SEC on August&nbsp;9, 2019, and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events
and circumstances discussed in such forward-looking statements may not occur, and UroGen‚Äôs actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date
of this press release and are based on information available to UroGen as of the date of this presentation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><b>UROGEN CONTACT: </b></p>
<p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Kate Bechtold </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Senior Director,&nbsp;Investor Relations </p>
<p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><u>Kate.Bechtold@urogen.com</u> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><font style="white-space:nowrap"><font style="white-space:nowrap">914-552-0456</font></font> </p>
</div></center>


</text>
</description></filename></sequence></type></document>
</body></html>Ytext/htmlUUTF-8    ( 7 N ` v î Î ÏkœkŸ                           kﬂ